Back
41
Also listed as
ANSLY
OTC
Day Range
$22.74
$22.74
52-Week Range
$18.00
$25.00
Volume
2,000
50D / 200D Avg
$22.83
/
$20.36
Prev Close
$22.74
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (627 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | 32.3 | 0.3 |
| P/B | 1.7 | 2.9 |
| ROE % | 5.3 | 3.7 |
| Net Margin % | 5.1 | 3.8 |
| Rev Growth 5Y % | -0.5 | 10.0 |
| D/E | 0.4 | 0.2 |
Analyst Price Target
No analyst coverage available
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2029 |
$1.80
$1.75 – $1.87
|
2.3 B | 5 |
| FY2028 |
$1.66
$1.61 – $1.72
|
2.2 B | 6 |
| FY2027 |
$1.56
$1.52 – $1.62
|
2.2 B | 5 |
Key Takeaways
Revenue declined -0.45% annually over 5 years
Earnings grew 32.81% over the past year
Debt/Equity of 0.41 — conservative balance sheet
Generating 170.00M in free cash flow
P/E of 32.30 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 24.16%
Growth
Revenue Growth (5Y)
-0.45%
Revenue (1Y)23.71%
Earnings (1Y)32.81%
FCF Growth (3Y)33.51%
Quality
Return on Equity
5.27%
ROIC2.95%
Net Margin5.07%
Op. Margin5.45%
Safety
Debt / Equity
0.41
Current Ratio2.13
Interest Coverage2.32
Valuation
P/E Ratio
32.30
P/B Ratio1.67
EV/EBITDA35.28
Dividend Yield0.02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 23.71% | Revenue Growth (3Y) | 10.72% |
| Earnings Growth (1Y) | 32.81% | Earnings Growth (3Y) | -17.23% |
| Revenue Growth (5Y) | -0.45% | Earnings Growth (5Y) | -19.89% |
| Profitability | |||
| Revenue (TTM) | 2.00B | Net Income (TTM) | 101.60M |
| ROE | 5.27% | ROA | 3.06% |
| Gross Margin | 41.18% | Operating Margin | 5.45% |
| Net Margin | 5.07% | Free Cash Flow (TTM) | 170.00M |
| ROIC | 2.95% | FCF Growth (3Y) | 33.51% |
| Safety | |||
| Debt / Equity | 0.41 | Current Ratio | 2.13 |
| Interest Coverage | 2.32 | Dividend Yield | 0.02% |
| Valuation | |||
| P/E Ratio | 32.30 | P/B Ratio | 1.67 |
| P/S Ratio | 1.64 | PEG Ratio | 1.27 |
| EV/EBITDA | 35.28 | Dividend Yield | 0.02% |
| Market Cap | 3.28B | Enterprise Value | 3.85B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.00B | 1.62B | 1.63B | 1.85B | 2.04B |
| Net Income | 101.60M | 76.50M | 148.30M | 158.70M | 246.70M |
| EPS (Diluted) | 0.71 | 0.59 | 1.15 | 1.18 | 1.91 |
| Gross Profit | 825.00M | 624.80M | 604.22M | 625.19M | 807.21M |
| Operating Income | 109.10M | 129.30M | 210.50M | 236.60M | 343.82M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 3.32B | 3.24B | 2.52B | 2.51B | 2.74B |
| Total Liabilities | 1.34B | 1.33B | 913.07M | 949.48M | 1.17B |
| Shareholders' Equity | 1.96B | 1.89B | 1.60B | 1.54B | 1.55B |
| Total Debt | 805.60M | 857.20M | 493.15M | 485.74M | 515.53M |
| Cash & Equivalents | 238.30M | 912.30M | 159.03M | 206.18M | 240.21M |
| Current Assets | 1.11B | 1.62B | 909.88M | 984.38M | 1.17B |
| Current Liabilities | 522.00M | 423.40M | 413.63M | 360.26M | 549.93M |
Strategy Scores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#608 of 1052
Recent Activity
Entered
Cash Flow Compounder
Mar 24, 2026